Skip to content
Preprint · OA via OpenAlex

Tissue Inhibitor of Matrix Metalloproteinase-3 or Vascular Endothelial Growth Factor Transfection of Aged Human Mesenchymal Stem Cells Enhances Cell Therapy after Myocardial Infarction

Jie Yao, Shulin Jiang, Wei Liu, Cheng Liu, Wei Chen, Lu Sun, Kai-Yu Liu, Zhibo Jia, Ren‐Ke Li, Hai Tian

Rejuvenation Research · 2012 · ▲ 30 citations

Abstract

Mesenchymal stem cell (MSC) transplantation has been proposed as a potential therapeutic approach for ischemic heart disease, but the regenerative capacity of these cells decreases with age. In this study, we genetically engineered old human MSCs (O-hMSCs) with tissue inhibitor of matrix metalloproteinase-3 (TIMP3) and vascular endothelial growth factor (VEGF) and evaluated the effects on the efficacy of cell-based gene therapy in a rat myocardial infarction (MI) model. Cultured O-hMSCs were transfected with TIMP3 (O-TIMP3) or VEGF (O-VEGF) and compared with young hMSCs (Y-hMSCs) and non-transfected O-hMSCs for growth, clonogenic capacity, and differentiation potential. In vivo, rats were subjected to left coronary artery ligation with subsequent injection of Y-hMSCs, O-hMSCs, O-TIMP3, O-VEGF, or medium. Echocardiography was performed prior to and at 1, 2, and 4 weeks after MI. Myocardial levels of matrix metalloproteinase-2 (MMP2), MMP9, TIMP3, and VEGF were assessed at 1 week. Hemodynamics, morphology, and histology were measured at 4 weeks. In vitro, genetically modified O-hMSCs showed no changes in growth, colony formation, or multi-differentiation capacity. In vivo, transplantation with O-TIMP3, O-VEGF, or Y-hMSCs increased capillary density, preserved cardiac function, and reduced infarct size compared to O-hMSCs and medium control. O-TIMP3 and O-VEGF transplantation enhanced TIMP3 and VEGF expression, respectively, in the treated animals. O-hMSCs genetically modified with TIMP3 or VEGF can increase angiogenesis, prevent adverse matrix remodeling, and restore cardiac function to a degree similar to Y-hMSCs. This gene-modified cell therapy strategy may be a promising clinical treatment to rejuvenate stem cells in elderly patients.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1089/rej.2012.1325
Canonical
link ↗
Fetched
2026-11-14 MST

Cite this

APA
Yao, J., Jiang, S., Liu, W., Liu, C., Chen, W., Sun, L., Liu, K., Jia, Z., Li, R., &amp; Tian, H. (2012). Tissue Inhibitor of Matrix Metalloproteinase-3 or Vascular Endothelial Growth Factor Transfection of Aged Human Mesenchymal Stem Cells Enhances Cell Therapy after Myocardial Infarction. <em>Rejuvenation Research</em>. https://doi.org/10.1089/rej.2012.1325
Vancouver
Yao J, Jiang S, Liu W, Liu C, Chen W, Sun L, et al. Tissue Inhibitor of Matrix Metalloproteinase-3 or Vascular Endothelial Growth Factor Transfection of Aged Human Mesenchymal Stem Cells Enhances Cell Therapy after Myocardial Infarction. Rejuvenation Research. 2012. doi:10.1089/rej.2012.1325.
BibTeX
@unpublished{jie2012Tissue, title = {Tissue Inhibitor of Matrix Metalloproteinase-3 or Vascular Endothelial Growth Factor Transfection of Aged Human Mesenchymal Stem Cells Enhances Cell Therapy after Myocardial Infarction}, author = {Jie Yao and Shulin Jiang and Wei Liu and Cheng Liu and Wei Chen and Lu Sun and Kai-Yu Liu and Zhibo Jia and Ren‐Ke Li and Hai Tian}, journal = {Rejuvenation Research}, year = {2012}, doi = {10.1089/rej.2012.1325}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings